Format

Send to

Choose Destination

Links from PubChem BioAssay

See comment in PubMed Commons below
Bioorg Med Chem Lett. 2012 Oct 1;22(19):6218-23. doi: 10.1016/j.bmcl.2012.08.015. Epub 2012 Aug 10.

Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes.

Author information

1
Amgen Inc, 1120 Veterans Blvd., South San Francisco, CA 94080, USA. xdu@amgen.com

Erratum in

  • Bioorg Med Chem Lett. 2012 Dec 15;22(24):7750.

Abstract

GPR142 is a novel GPCR that is predominantly expressed in pancreatic β-cells. GPR142 agonists potentiate glucose-dependent insulin secretion, and therefore can reduce the risk of hypoglycemia. Optimization of our lead pyridinone-phenylalanine series led to a proof-of-concept compound 22, which showed in vivo efficacy in mice with dose-dependent increase in insulin secretion and a decrease in glucose levels.

PMID:
22926069
DOI:
10.1016/j.bmcl.2012.08.015
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center